SLDB - NASDAQ
Solid Biosciences Inc.
$7.35
+12%Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotSolid Biosciences Inc. Management Team
Mr. Kevin Tan C.F.A.
Chief Financial Officer & Treasurer
Compensation
$607,181
Dr. Gabriel Brooks M.D.
Chief Medical Officer
Compensation
$667,107
Mr. David Tyronne Howton Jr., J.D.
Chief Operating Officer & Secretary
Compensation
$674,900
Mr. Paul Herzich
Chief Technology Officer
Ms. Annie Ganot
Co-Founder & Vice President of Patient Advocacy
Mr. Ilan Ganot
Co-founder, Strategic Advisor to the Chief Executive Officer & Director
Compensation
$281,145
Ms. Nicole Anderson
Director of Investor Relations & Corporate Communications
Mr. Ian F. Smith A.C.A., C.P.A.
Executive Chair
Compensation
$75,000
Mr. Alexander G. Cumbo
President, Chief Executive Officer & Director
Compensation
$955,440
Ms. Allison Bogosian J.D.
Senior Vice President of Human Resources
Solid Biosciences Inc. Insider Positioning
During the last 12 months, insiders have purchased $3.19M and sold $2.68M worth of SLDB shares, resulting in $513K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
398.5K
2.53M
-2.5M
-$2.53M
6-9 Months
0
0.00
29.1K
147.90K
-148K
-$148K
9-12 Months
697.5K
3.19M
0
0.00
+3.2M
+$3.19M
Top Buyers
Keresty Georgia
Director
$355K
Stone Adam Leo
Director
$355K
Sullivan Lynne Marie
Director
$355K
Ganot Ilan
Director
$355K
Kahn Clare
Director
$355K
Top Sellers
Cumbo Alexander
Director, Officer: President And Ceo
$984K
Howton David T
Officer: Chief Operating Officer
$434K
Tan Kevin
Officer: Cfo & Treasurer
$330K
Hanrahan Jessie
Officer: Chief Regulatory Officer
$297K
Brooks Gabriel
Officer: Chief Medical Officer
$281K
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $513K net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
SEC Filings
SLDB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 10, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 11, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 27, 2023 | June 06, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2021 | June 16, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 28, 2020 | June 16, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | May 03, 2019 | June 13, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.